Literature DB >> 28976792

Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study.

Xuexia Wang1, Can-Lan Sun1, Lindsey Hageman1, Kandice Smith1, Purnima Singh1, Sunil Desai1, Douglas S Hawkins1, Melissa M Hudson1, Leo Mascarenhas1, Joseph P Neglia1, Kevin C Oeffinger1, A Kim Ritchey1, Leslie L Robison1, Doojduen Villaluna1, Wendy Landier1, Smita Bhatia1.   

Abstract

Purpose Survivors of childhood cancer treated with cranial radiation therapy are at risk for subsequent CNS tumors. However, significant interindividual variability in risk suggests a role for genetic susceptibility and provides an opportunity to identify survivors of childhood cancer at increased risk for these tumors. Methods We curated candidate genetic variants from previously published studies in adult-onset primary CNS tumors and replicated these in survivors of childhood cancer with and without subsequent CNS tumors (82 participants and 228 matched controls). We developed prediction models to identify survivors at high or low risk for subsequent CNS tumors and validated these models in an independent matched case-control sample (25 participants and 54 controls). Results We demonstrated an association between six previously published single nucleotide polymorphisms (rs15869 [ BRCA2], rs1805389 [ LIG4], rs8079544 [ TP53], rs25489 [ XRCC1], rs1673041 [ POLD1], and rs11615 [ ERCC1]) and subsequent CNS tumors in survivors of childhood cancer. Including genetic variants in a Final Model containing age at primary cancer, sex, and cranial radiation therapy dose yielded an area under the curve of 0.81 (95% CI, 0.76 to 0.86), which was superior ( P = .002) to the Clinical Model (area under the curve, 0.73; 95% CI, 0.66 to 0.80). The prediction model was successfully validated. The sensitivity and specificity of predicting survivors of childhood cancer at highest or lowest risk of subsequent CNS tumors was 87.5% and 83.5%, respectively. Conclusion It is possible to identify survivors of childhood cancer at high or low risk for subsequent CNS tumors on the basis of genetic and clinical information. This information can be used to inform surveillance for early detection of subsequent CNS tumors.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28976792      PMCID: PMC5678343          DOI: 10.1200/JCO.2017.74.7444

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  31 in total

Review 1.  Mechanism and regulation of human non-homologous DNA end-joining.

Authors:  Michael R Lieber; Yunmei Ma; Ulrich Pannicke; Klaus Schwarz
Journal:  Nat Rev Mol Cell Biol       Date:  2003-09       Impact factor: 94.444

2.  Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.

Authors:  Aliki J Taylor; Mark P Little; David L Winter; Elaine Sugden; David W Ellison; Charles A Stiller; Marilyn Stovall; Clare Frobisher; Emma R Lancashire; Raoul C Reulen; Michael M Hawkins
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

3.  Joint associations between genetic variants and reproductive factors in glioma risk among women.

Authors:  Sophia S Wang; Patricia Hartge; Meredith Yeager; Tania Carreón; Avima M Ruder; Martha Linet; Peter D Inskip; Amanda Black; Ann W Hsing; Michael Alavanja; Laura Beane-Freeman; Mahboobeh Safaiean; Stephen J Chanock; Preetha Rajaraman
Journal:  Am J Epidemiol       Date:  2011-09-13       Impact factor: 4.897

4.  A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.

Authors:  Simon N Stacey; Patrick Sulem; Aslaug Jonasdottir; Gisli Masson; Julius Gudmundsson; Daniel F Gudbjartsson; Olafur T Magnusson; Sigurjon A Gudjonsson; Bardur Sigurgeirsson; Kristin Thorisdottir; Rafn Ragnarsson; Kristrun R Benediktsdottir; Bjørn A Nexø; Anne Tjønneland; Kim Overvad; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Cristina Corredera; Victoria Fuentelsaz; Pilar Grasa; Sebastian Navarrete; Fernando Fuertes; Maria D García-Prats; Enrique Sanambrosio; Angeles Panadero; Ana De Juan; Almudena Garcia; Fernando Rivera; Dolores Planelles; Virtudes Soriano; Celia Requena; Katja K Aben; Michelle M van Rossum; Ruben G H M Cremers; Inge M van Oort; Dick-Johan van Spronsen; Jack A Schalken; Wilbert H M Peters; Brian T Helfand; Jenny L Donovan; Freddie C Hamdy; Daniel Badescu; Ovidiu Codreanu; Mariana Jinga; Irma E Csiki; Vali Constantinescu; Paula Badea; Ioan N Mates; Daniela E Dinu; Adrian Constantin; Dana Mates; Sjofn Kristjansdottir; Bjarni A Agnarsson; Eirikur Jonsson; Rosa B Barkardottir; Gudmundur V Einarsson; Fridbjorn Sigurdsson; Pall H Moller; Tryggvi Stefansson; Trausti Valdimarsson; Oskar T Johannsson; Helgi Sigurdsson; Thorvaldur Jonsson; Jon G Jonasson; Laufey Tryggvadottir; Terri Rice; Helen M Hansen; Yuanyuan Xiao; Daniel H Lachance; Brian Patrick O Neill; Matthew L Kosel; Paul A Decker; Gudmar Thorleifsson; Hrefna Johannsdottir; Hafdis T Helgadottir; Asgeir Sigurdsson; Valgerdur Steinthorsdottir; Annika Lindblom; Robert S Sandler; Temitope O Keku; Karina Banasik; Torben Jørgensen; Daniel R Witte; Torben Hansen; Oluf Pedersen; Viorel Jinga; David E Neal; William J Catalona; Margaret Wrensch; John Wiencke; Robert B Jenkins; Eduardo Nagore; Ulla Vogel; Lambertus A Kiemeney; Rajiv Kumar; José I Mayordomo; Jon H Olafsson; Augustine Kong; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2011-09-25       Impact factor: 38.330

5.  High incidence of secondary brain tumours after radiotherapy and antimetabolites.

Authors:  M V Relling; J E Rubnitz; G K Rivera; J M Boyett; M L Hancock; C A Felix; L E Kun; A W Walter; W E Evans; C H Pui
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

6.  XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions.

Authors:  A E Vidal; S Boiteux; I D Hickson; J P Radicella
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

7.  Analysis of DNA repair gene polymorphisms in glioblastoma.

Authors:  Irene Rodriguez-Hernandez; Sandra Perdomo; Angel Santos-Briz; Juan Luis Garcia; Juan Antonio Gomez-Moreta; Juan Jesus Cruz; Rogelio Gonzalez-Sarmiento
Journal:  Gene       Date:  2013-12-08       Impact factor: 3.688

Review 8.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.

Authors:  Kyle M Walsh; Terri Rice; Paul A Decker; Matthew L Kosel; Thomas Kollmeyer; Helen M Hansen; Shichun Zheng; Lucie S McCoy; Paige M Bracci; Erik Anderson; George Hsuang; Joe L Wiemels; Alexander R Pico; Ivan Smirnov; Annette M Molinaro; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Daniel H Lachance; Hugues Sicotte; Jeanette E Eckel-Passow; John K Wiencke; Robert B Jenkins; Margaret R Wrensch
Journal:  Neuro Oncol       Date:  2013-06-03       Impact factor: 12.300

10.  Survival and late mortality in long-term survivors of pediatric CNS tumors.

Authors:  E Brannon Morris; Amar Gajjar; James O Okuma; Yutaka Yasui; Dana Wallace; Larry E Kun; Thomas E Merchant; Maryam Fouladi; Alberto Broniscer; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

View more
  7 in total

Review 1.  Regulatory mechanisms and potential medical applications of HNF1A-AS1 in cancers.

Authors:  Yang Zhang; Jiang Shi; Junfang Luo; Cong Liu; Lixu Zhu
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

2.  Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research.

Authors:  Eric J Chow; Lena E Winestone; Philip J Lupo; Lisa R Diller; Tara O Henderson; Nina S Kadan-Lottick; Jennifer M Levine; Kirsten K Ness; Smita Bhatia; Saro H Armenian
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-09-02       Impact factor: 4.090

3.  Polygenic Risk Score Improves Risk Stratification and Prediction of Subsequent Thyroid Cancer after Childhood Cancer.

Authors:  Nan Song; Qi Liu; Yutaka Yasui; Zhaoming Wang; Carmen L Wilson; Yadav Sapkota; Matthew J Ehrhardt; Todd M Gibson; Lindsay M Morton; Stephen J Chanock; Joseph P Neglia; Michael A Arnold; J Robert Michael; Alexander M Gout; Heather L Mulder; John Easton; Smita Bhatia; Gregory T Armstrong; Jinghui Zhang; Angela Delaney; Melissa M Hudson; Leslie L Robison
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-08-31       Impact factor: 4.090

Review 4.  The Achilles' heel of cancer survivors: fundamentals of accelerated cellular senescence.

Authors:  Shameel Shafqat; Evelyn Arana Chicas; Areez Shafqat; Shahrukh K Hashmi
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

Review 5.  Current and coming challenges in the management of the survivorship population.

Authors:  Eric J Chow; Kirsten K Ness; Gregory T Armstrong; Nickhill Bhakta; Jennifer M Yeh; Smita Bhatia; Wendy Landier; Louis S Constine; Melissa M Hudson; Paul C Nathan
Journal:  Semin Oncol       Date:  2020-03-04       Impact factor: 4.929

6.  Ferroptosis-Related Gene Contributes to Immunity, Stemness and Predicts Prognosis in Glioblastoma Multiforme.

Authors:  Jiawei Dong; Hongtao Zhao; Fang Wang; Jiaqi Jin; Hang Ji; Xiuwei Yan; Nan Wang; Jiheng Zhang; Shaoshan Hu
Journal:  Front Neurol       Date:  2022-03-10       Impact factor: 4.003

7.  Prognostic Model and Nomogram Construction and Validation With an Autophagy-Related Gene Signature in Low-Grade Gliomas.

Authors:  Xinrui Li; Zhiyuan Huang; Lei Zhu; Fei Yu; Minghao Feng; Aiqin Gu; Jianxin Jiang; Guangxue Wang; Dongya Huang
Journal:  Front Genet       Date:  2022-07-18       Impact factor: 4.772

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.